For confirmation, CD34+ cells from MPL-mutated MPN patients were also assessed showing analogous effects upon combined JAK2/ERK1/2 inhibition to JAK2V617F patients, while CD34+ cells from healthy donors were evaluated as controls (Supplementary Fig. 13E-J). Here, MAPK3 is linked to myeloproliferative neoplasm.